COGT Stock Analysis: Cogent Biosciences | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 6.394m USD | 12M Return: 212.1% | US19240Q2012 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 65.1M
Warnings
Tailwinds
Seasonality 8.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cogent Biosciences, Inc. (NASDAQ: COGT) is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, that develops precision therapies for genetically defined diseases. Its lead candidate, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor currently in Phase 3 trials, targeting the KIT D816V mutation associated with systemic mastocytosis and KIT exon 17 mutations found in advanced gastrointestinal stromal tumors (GIST). The company holds a licensing agreement with Plexxikon Inc. for the development and commercialization of bezuclastinib.
The pipeline also includes CGT4859, a selective FGFR2 inhibitor in Phase 1 for cancers with FGFR mutations such as advanced cholangiocarcinoma, along with earlier-stage programs targeting ErbB2 (CGT4255) and PI3Kα (CGT6297) mutations in solid tumors. As a clinical-stage biotech, Cogent does not yet have approved products or recurring product revenue, and its valuation is largely tied to the progress of its clinical pipeline and the likelihood of regulatory approval. The company operates within the GICS Health Care sector, Biotechnology sub-industry, and is classified as a mid-cap stock.
- Bezuclastinib Phase 3 SUMMIT trial readout in systemic mastocytosis approaches
- Blueprint Medicines Ayvakit dominates approved systemic mastocytosis market
- Cash runway extends operations through key clinical milestones
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.38 > 0.02 and ΔFCF/TA 49.87 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.37 > 3% & CFO -307.5m > Net Income -377.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (171.0m) vs 12m ago 50.10% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 1.56%; Δ -1.56% > 0%) |
| Interest Coverage Ratio: -72.72 > 6 (EBIT TTM -376.5m / Interest Expense TTM 5.18m) |
| A: 0.89 (Total Current Assets 804.8m - Total Current Liabilities 59.3m) / Total Assets 834.5m |
| B: -1.66 (Retained Earnings -1.38b / Total Assets 834.5m) |
| C: -0.68 (EBIT TTM -376.5m / Avg Total Assets 554.7m) |
| D: 1.76 (Book Value of Equity 532.4m / Total Liabilities 302.2m) |
| Altman-Z'' = -2.25 = D |
As of August 22, 2026, the stock is trading at USD 36.73 with a total of 2,515,751 shares traded. Over the past week, the price has changed by -3.16%, over one month by -7.34%, over three months by +12.74% and over the past year by +212.06%.
Current recommended Stop Loss: 34.50 (which is 6.1% or 1.2 ATR below the current price).
Cogent Biosciences has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy COGT.
- StrongBuy: 5
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 53.8 | 46.6% |
P/S = 861.1519
P/B = 13.878
Revenue TTM = 0.0 USD
EBIT TTM = -376.5m USD
EBITDA TTM = -372.9m USD
Long Term Debt = 222.9m USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.49m USD (from shortTermDebt, last quarter)
Debt = 259.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 15.5m
Net Debt = -516.9m USD (calculated: Debt 259.7m - CCE 776.6m)
Enterprise Value = 5.88b USD (6.39b + Debt 259.7m - CCE 776.6m)
Interest Coverage Ratio = -72.72 (Ebit TTM -376.5m / Interest Expense TTM 5.18m)
EV/FCF = -18.70x (Enterprise Value 5.88b / FCF TTM -314.3m)
FCF Yield = -5.35% (FCF TTM -314.3m / Enterprise Value 5.88b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 4.62m) / Revenue TTM)
Tobins Q-Ratio = 7.04 (Enterprise Value 5.88b / Total Assets 834.5m)
Interest Expense / Debt = 1.99% (Interest Expense 5.18m / Debt 259.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -297.5m (EBIT -376.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.05 (Total Current Assets 804.8m / Total Current Liabilities 66.8m)
Debt / Equity = 0.49 (Debt 259.7m / totalStockholderEquity, last quarter 532.4m)
Debt / EBITDA = 1.39 (negative EBITDA) (Net Debt -516.9m / EBITDA -372.9m)
Debt / FCF = 1.64 (negative FCF - burning cash) (Net Debt -516.9m / FCF TTM -314.3m)
Total Stockholder Equity = 519.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -68.00% (Net Income -377.2m / Total Assets 834.5m)
RoE = -72.57% (Net Income TTM -377.2m / Total Stockholder Equity 519.7m)
RoCE = -50.70% (EBIT -376.5m / Capital Employed (Equity 519.7m + L.T.Debt 222.9m))
RoIC = -38.30% (negative operating profit) (NOPAT -297.5m / Invested Capital 776.7m)
WACC = 11.39% (E(6.39b)/V(6.65b) * Re(11.79%) + D(259.7m)/V(6.65b) * Rd(1.99%) * (1-Tc(0.21)))
Discount Rate = 11.79% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.94 | Cagr: 29.97%
[DCF] Fair Price = unknown (Cash Flow -314.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.16 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.56 | Chg30d=+2.36% | Revisions=-25% | Analysts=7
EPS current Year (2026-12-31): EPS=-2.21 | Chg30d=+1.83% | Revisions=-42% | GrowthEPS=-4.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.13 | Chg30d=-17.86% | Revisions=+25% | GrowthEPS=+49.1% | GrowthRev=+5462.5%
[Analyst] Revisions Ratio: -36% (up=3, down=8)